Pricing Log in Create free account
Friday 6 November 2026 Export ANGO’s income statement to Excel — free account

AngioDynamics, Inc.

ANGO Healthcare Medical Instruments & Supplies

AngioDynamics, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $320.2 million, up 9.46% from fiscal 2025.

Revenue
+6.87%
EPS
+34.6%
Free cash flow
+5.62%

Quarter to August 2026, against a year earlier

11.69 0.12 −1.02%
Market cap
$496.7M
P/E
0.0×
Fwd P/E
−17.6×
Dividend yield
—
F-score
5/9
Altman Z
1.63
Beneish M
−3.08
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.65
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — 1 — — 1 —
Insider Ownership 11.45%

Capital & Financial Ratios $m

Size
Market Cap 496.67
Revenue ttm 325.38
Net income ttm (32.94)
Free cash flow ttm 1.44
Net debt Q (33.97)
Valuation
P/E 0.00
Forward P/E (17.60) (negative: loss-making)
Price / sales 1.51
Forward P/S Powerpack
Price / FCF 0.00
Price / book 3.00
Financial health
Current ratio Q 2.40 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (82.98)
Growth
Revenue growth Q +6.87% (above 0%: growing)
Operating income growth Q +31.48% (above 0%: growing)
EPS, this year −82.03% (below 0%: weak)
EPS, next year A +61.55% (at or above 15%: strong)
Revenue, next year A +5.47%
EPS, past 5 yrs —
EPS, next 5 yrs A +41.52% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.6×, against a ten-year median of 1.9×; over the ten years it ranged from 0.6× in 2024 to 4.6× in 2019.
P/S against its own 10 years 35.96%
10-year low 10-year high
P/B against its own 10 years 95.86%
10-year low 10-year high
EV/Sales against its own 10 years 36.51%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 76 56 54 34
Receivables 44 43 48 45
Inventory 61 62 52 55
Other — — — —
193 168 163 143
2024 2025 2026 Q'26
Payables 38 33 32 27
ST’ Debt — — — —
Other 12 7 4 4
91 76 75 60

Compound Annual Growth %

10y 5y 3y
Sales (1.00%) 1.93% (1.86%)
Cash Flow (23.54%) (33.69%) 240.86%
Earnings 0.00% 0.00% 0.00%
Book Value (10.31%) (17.22%) (23.28%)

Earnings Trends EPS, adjusted, against the consensus

Q1 FY27 Estimate −0.10 Actual −0.04

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY26 −0.10 0.00 Beat by 0.10
Q3 FY26 −0.11 −0.07 Beat by 0.04
Q4 FY26 −0.11 −0.07 Beat by 0.04
Q1 FY27 −0.10 −0.04 Beat by 0.06
Q2 FY27 −0.11 — Reports 5 January 2027

EPS $

Aug Nov Feb May Year
’26 (0.17) — — — —
’26 (0.26) (0.15) (0.19) (0.27) (0.88)
’25 (0.31) (0.26) (0.11) (0.15) (0.83)
’24 1.15 (0.72) (4.73) (0.33) (4.59)
’23 (0.33) (0.21) (0.24) (0.54) (1.33)
’22 (0.18) (0.21) (0.13) (0.16) (0.68)
’21 (0.11) (0.11) (0.09) (0.51) (0.82)
Fiscal quarters ending in the months shown.

Revenue $m

Aug Nov Feb May Year
’26 81 — — — —
’26 76 79 78 87 320
’25 67 73 72 80 292
’24 79 79 75 71 304
’23 82 85 81 91 339
’22 77 78 74 87 316
’21 70 73 71 77 291
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Aug Nov Feb May Year
’26 (15) — — — —
’26 (16) 5 (3) 17 3
’25 (18) 2 (13) 19 (10)
’24 (26) 5 (13) 5 (28)
’23 (25) 7 1 16 0
’22 (9) 2 (9) 9 (7)
’21 (5) 11 6 12 24
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Aug Nov Feb May Year
’26 (16) — — — —
’26 (17) 4 (4) 17 1
’25 (19) 2 (15) 18 (15)
’24 73 5 18 4 101
’23 (26) 6 0 15 (4)
’22 (10) 1 (10) 8 (11)
’21 (7) 10 4 12 19
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to May

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 TTM Aug ’26 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 270 262 271 264 291 316 339 304 292 320 325 +1.9% 338 355 375 +5.4%
Gross margin, % 53.36 54.98 57.64 56.89 53.88 52.41 51.44 50.90 53.92 54.62 55.65 +1.3 pt
EBT (14) (17) (15) (168) (36) (30) (54) (192) (34) (36) (33) +10.9%
EBT margin, % (5.30) (6.60) (5.43) (63.65) (12.39) (9.47) (16.07) (63.06) (11.63) (11.34) (10.07) (6.0) pt
Net income 5 16 61 (167) (32) (27) (52) (184) (34) (37) (33) n/m
Per share, $
Per share, $ Revenue 7.37 7.06 7.22 6.96 7.59 8.11 8.58 7.56 7.16 7.71 7.74 +0.5%
Earnings 0.14 0.44 1.64 (4.37) (0.82) (0.68) (1.33) (4.59) (0.83) (0.88) (0.78) n/m
Cash flow 1.52 1.11 1.00 (0.38) 0.63 (0.18) 0.00 (0.70) (0.25) 0.07 0.09 (28.5%)
Capex (0.08) (0.10) (0.08) (0.20) (0.14) (0.11) (0.11) 3.20 (0.11) (0.06) (0.05) (3.0%)
Free cash flow 1.44 1.02 0.92 (0.58) 0.49 (0.29) (0.11) 2.50 (0.36) 0.01 0.03 (41.1%)
Book value 14.07 14.64 16.40 11.98 11.46 10.88 9.58 5.12 4.48 4.11 3.90 (12.8%)
Shares, m 37 37 37 38 38 39 39 40 41 42 42 +1.4%
Valuation, ×
Valuation, × P/E 79.37 47.17 11.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.8
P/S 2.05 2.98 2.60 1.49 3.09 2.42 1.10 0.83 1.35 1.42 1.51 1.9
P/B 1.07 1.44 1.15 0.87 2.05 1.80 0.99 1.23 2.17 2.65 3.00 1.5
EV/Sales 2.22 3.04 2.25 1.47 3.02 2.43 1.14 0.77 1.35 1.42 1.57 1.9
EV/FCF 12.46 23.16 20.43 (17.48) 47.42 (64.98) (80.22) 2.35 (21.50) (138.33) (218.28) (21.7)
Cash, $m
Cash, $m Operating cash flow 56 41 37 (15) 24 (7) 0 (28) (10) 3 4 (27.5%)
Capex (3) (4) (3) (8) (5) (4) (4) 129 (4) (3) (2) (1.7%)
Free cash flow 53 38 34 (22) 19 (11) (4) 101 (15) 1 1 (40.3%)
Balance, $m
Balance, $m Working capital 82 111 242 101 83 69 80 102 92 89 83 +0.8%
Net debt 48 16 (96) (14) (28) (4) 5 (76) (56) (54) (34) n/m
Shareholders’ equity 515 543 615 455 439 424 378 206 183 171 164 (11.5%)
Returns, %
Returns, % ROA 0.70 2.31 7.96 (23.32) (5.46) (4.77) (9.66) (43.36) (11.37) (13.43) (12.98) (14.1) pt
ROIC (1.24) (1.58) (1.13) (23.71) (5.36) (4.23) (8.34) (92.85) (19.65) (21.34) (17.58) (20.1) pt
ROE 0.98 3.09 10.60 (31.18) (7.06) (6.15) (13.07) (63.15) (17.50) (20.77) (19.21) (21.7) pt
People
People Employees 1,250 1,145 1,050 800 800 760 815 748 675 632 — (7.3%)
Revenue/emp, $m 0.22 0.23 0.26 0.33 0.36 0.42 0.42 0.41 0.43 0.51 — +9.9%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to May 2026 · latest quarter Aug 2026 · fundamentals updated 2 Nov 2026

AngioDynamics, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
STAA STAAR Surgical Company $1.3B 84,233× 84.4× −11.95% (below 0%: shrinking) −38.72% (below 0%: shrinking) +1,378.70% (above 0%: growing) 70.90% 6.54% Compare
NNNN Anbio Biotechnology $516.6M — — — — — — — Compare
ZJYL Jin Medical International Ltd. $509.4M — — — — −8,074.17% (below 0%: shrinking) 34.44% 0.00% Compare
ANGO AngioDynamics, Inc. $496.7M — (loss-making) — (loss-making) +6.87% (above 0%: growing) n/m +5.62% (above 0%: growing) 59.37% (9.02%)
EMBC Embecta Corp. $358.7M 4.2× 5.3× −8.05% (below 0%: shrinking) −53.85% (below 0%: shrinking) −49.63% (below 0%: shrinking) 56.42% 17.92% Compare
SMTI Sanara MedTech Inc. $290.4M — (loss-making) 164× +9.04% (above 0%: growing) n/m +131.28% (above 0%: growing) 92.96% 6.33% Compare
OSUR OraSure Technologies, Inc. $232.4M — (loss-making) — (loss-making) −1.93% (below 0%: shrinking) n/m −1.40% (below 0%: shrinking) 43.46% 17.76% Compare
UTMD Utah Medical Products, Inc. $202.4M 22.0× 28.7× −14.31% (below 0%: shrinking) −10.64% (below 0%: shrinking) −55.74% (below 0%: shrinking) 55.79% 31.06% Compare
PDEX Pro-Dex, Inc. $195.8M 16.8× 18.8× +10.96% (above 0%: growing) −33.52% (below 0%: shrinking) +177.76% (above 0%: growing) 33.35% 17.10% Compare
Median of peers $324.5M 19.4× 28.7× −4.99% −36.12% −1.40% 55.79% 17.10%

All 53 Medical Instruments & Supplies stocks →

Pay and ownership Proxy statement filed 8 October 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2026 6.06m 13.69m 49.65
2025 5.49m 6.81m 44.12
2024 5.01m 971.11k 27.29
2023 3.98m (2.11m) 40.92
2022 5.66m 4.95m 84.90
2021 4.05m 13.88m 226.44

Ownership

Directors and executive officers, together 6.00%
Point72 Asset Management, L.P. 7.70%
BlackRock, Inc. 7.10%
Systematic Financial Management LP 6.10%
Kevin Kotler c/o Broadfin Holdings, LLC 5.90%
Millennium Management LLC 5.20%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

AngioDynamics, Inc. (ANGO) Latest News

29 Oct

Impact 3 · · Business Wire

21 Oct

Impact 4 · · Business Wire

14 Oct

Impact 4 · · Business Wire

9 Oct

Impact 3 · · Zacks

8 Oct

Impact 4 · · Moby
Impact 4 · · The Motley Fool
Impact 4 · · Investing.com
Impact 4 · · Business Wire
Impact 4 · · Business Wire
Impact 3 · · The Motley Fool transcript
Impact 3 · · MarketBeat
Impact 3 · · InvestorsHub
Impact 3 · · Zacks
Impact 3 · · Associated Press

2 Oct

Impact 3 · · Business Wire

11 Aug

Impact 4 · · MarketBeat

6 Aug

Impact 3 ·
Impact 3 ·

21 Jul

Impact 4 · · The Motley Fool transcript

15 Jul

Impact 3 · · Moby transcript

14 Jul

Impact 4 · · MarketBeat transcript
Impact 4 · · InvestorsHub
Impact 4 ·
Impact 3 ·
Impact 3 ·
Impact 3 ·

18 Jun

Impact 3 ·

17 Jun

Impact 3 ·

28 May

Impact 4 · · Business Wire

13 May

Impact 4 · · Business Wire
stockrow.com/ANGO · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com